Aegerion Pharmaceuticals, Inc.
(NASDAQ : AEGR)

( )
AEGR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.04%53.990.9%$1408.53m
JNJJohnson & Johnson 0.02%179.580.7%$1296.73m
BMYBristol-Myers Squibb Co. 0.52%77.991.0%$1218.41m
MRKMerck & Co., Inc. -0.31%92.030.7%$1163.36m
ABBVAbbVie, Inc. 0.34%151.071.9%$1104.03m
LLYEli Lilly & Co. -0.15%313.001.1%$965.80m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.14%142.980.0%$491.89m
AZNAstraZeneca Plc -0.12%66.621.0%$490.91m
NVSNovartis AG -0.57%90.740.2%$258.37m
GSKGlaxoSmithKline Plc -0.42%44.230.2%$256.49m
VERUVeru, Inc. -0.16%12.620.0%$253.31m
HZNPHorizon Therapeutics Plc 0.00%90.595.4%$196.03m
SGENSeagen Inc. 0.00%138.465.7%$185.67m
NVONovo Nordisk A/S -1.18%105.360.1%$180.73m
VTRSViatris, Inc. -0.42%11.960.0%$164.58m

Company Profile

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.